Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B

被引:34
|
作者
Han, E. [1 ]
Lee, Y. -H. [2 ,3 ]
Kim, B. K. [2 ,4 ]
Park, J. Y. [2 ,4 ]
Kim, D. Y. [2 ,4 ]
Ahn, S. H. [2 ,4 ]
Lee, B. -W. [2 ,3 ]
Kang, E. S. [2 ,3 ]
Cha, B. -S. [2 ,3 ]
Han, K. -H. [2 ,4 ]
Kim, S. U. [2 ,4 ]
机构
[1] Keimyung Univ, Sch Med, Dept Internal Med, Daegu, South Korea
[2] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[3] Yonsei Univ, Coll Med, Inst Endocrine Res, Seoul, South Korea
[4] Yonsei Univ, Coll Med, Inst Gastroenterol, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
SURVEYS KNHANES 2008-2011; INSULIN-RESISTANCE; HEPATOCELLULAR-CARCINOMA; FOLLOW-UP; DISEASE; CIRRHOSIS; DIAGNOSIS; MANAGEMENT; NUTRITION; STEATOHEPATITIS;
D O I
10.1111/apt.14843
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Sarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in individuals with chronic hepatitis B. Methods: Data from the Korean National Health and Nutrition Examination Surveys 2008-2011 were analysed. The sarcopenia index (total appendicular skeletal muscle mass [kg]/body mass index [kg/m(2)]) was calculated using dual-energy X-ray absorptiometry. Sarcopenia was defined as the lowest quintile sarcopenia index value (cutoffs: 0.89 for men and 0.58 for women). The fibrotic burden was assessed using the nonalcoholic fatty liver disease fibrosis score and fibrosis-4 index. Significant fibrosis was defined as the highest nonalcoholic fatty liver disease fibrosis score quartile and a fibrosis-4 index >= 2.67. Results: Among the 506 respondents with chronic hepatitis B (258 men and 248 women), the nonalcoholic fatty liver disease fibrosis score and fibrosis-4 index identified sarcopenia and significant fibrosis in 126 (24.9%) and 217 (42.9%), respectively. Sarcopenia was significantly associated with significant fibrosis, regardless of the fibrosis prediction model used (all P < 0.05). When the study population was stratified according to metabolic factors, sarcopenia was specifically associated with an increased risk of significant fibrosis among subgroups with obesity, insulin resistance, metabolic syndrome and liver steatosis (odds ratio 2.37-3.57; all P < 0.05). An independent association between sarcopenia and significant fibrosis was identified after adjusting for other confounders (odds ratio 2.67-3.62 by the nonalcoholic fatty liver disease fibrosis score and 2.04-2.62 by the fibrosis-4 index; all P < 0.05). Conclusions: Sarcopenia is associated with significant fibrosis in subjects with chronic hepatitis B, specifically those with obesity, insulin resistance, metabolic syndrome and liver steatosis.
引用
收藏
页码:300 / 312
页数:13
相关论文
共 50 条
  • [1] Decreasing Hepatitis B Viral Load is Associated With a Risk of Significant Liver Fibrosis in Hepatitis B e Antigen Positive Chronic Hepatitis B
    Xie, Qinxiu
    Hu, Xiangyang
    Zhang, Yafei
    Jiang, Xiaoping
    Li, Xu
    Li, Jiabin
    JOURNAL OF MEDICAL VIROLOGY, 2014, 86 (11) : 1828 - 1837
  • [2] Sarcopenia assessed using bioimpedance analysis is associated independently with significant liver fibrosis in patients with chronic liver diseases
    Kim, Kyung Hyun
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Han, Kwang-Hyub
    Kim, Seung Up
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 32 (01) : 58 - 65
  • [3] Platelets' increase is associated with improvement of liver fibrosis in entecavir-treated chronic hepatitis B patients with significant liver fibrosis
    Wang, Lin
    Wang, Bingqiong
    You, Hong
    Wu, Xiaoning
    Zhou, Jialing
    Ou, Xiaojuan
    Jia, Jidong
    HEPATOLOGY INTERNATIONAL, 2018, 12 (03) : 237 - 243
  • [4] Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B
    Croagh, Catherine M. N.
    Bell, Sally J.
    Slavin, John
    Kong, Yu X. G.
    Chen, Robert Y.
    Locarnini, Stephen
    Desmond, Paul V.
    LIVER INTERNATIONAL, 2010, 30 (08) : 1115 - 1122
  • [5] Risk factors associated with liver steatosis and fibrosis in chronic hepatitis B patient with component of metabolic syndrome
    Cai, Shaohang
    Ou, Zejin
    Liu, Duan
    Liu, Lili
    Liu, Ying
    Wu, Xiaolu
    Yu, Tao
    Peng, Jie
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2018, 6 (04) : 558 - 566
  • [6] High Prevalence of Significant Liver Fibrosis and Cirrhosis in Chronic Hepatitis B Patients With Normal ALT in Central Europe
    Goebel, Thomas
    Erhardt, Andreas
    Herwig, Mathias
    Poremba, Christopher
    Baldus, Stephan Ernst
    Sagir, Abdurrahman
    Heinzel-Pleines, Ulrike
    Haeussinger, Dieter
    JOURNAL OF MEDICAL VIROLOGY, 2011, 83 (06) : 968 - 973
  • [7] Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease
    Hong, Shan
    Hao, Yiwei
    Sun, Lei
    Li, Ping
    Yang, Junru
    Zhang, Fuyang
    He, Lingling
    Zhang, Jing
    Wei, Hongshan
    ANNALS OF HEPATOLOGY, 2025, 30 (02)
  • [8] Noninvasive evaluation of significant liver fibrosis in chronic hepatitis B patients
    Dilcan, K. H.
    Gozdas, H. T.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2024, 87 (03) : 388 - 392
  • [9] Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B
    Tsuji, Yuki
    Namisaki, Tadashi
    Kaji, Kosuke
    Takaya, Hiroaki
    Nakanishi, Keisuke
    Sato, Shinya
    Saikawa, Soichiro
    Sawada, Yasuhiko
    Kitagawa, Kou
    Shimozato, Naotaka
    Kawaratani, Hideto
    Moriya, Kei
    Noguchi, Ryuichi
    Akahane, Takemi
    Mitoro, Akira
    Yoshiji, Hitoshi
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 20 (02) : 985 - 995
  • [10] A Novel Prediction Model for Significant Liver Fibrosis in Patients with Chronic Hepatitis B
    Chen, Yaqiong
    Gong, Jiao
    Zhou, Wenying
    Jie, Yusheng
    Li, Zhaoxia
    Chong, Yutian
    Hu, Bo
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020